ClinicalTrials.gg
Not yet recruitingNCT07940452Updated Nov 16, 2026

A Novel Eye Wash Solution for DED Treatment

An Early Phase 1 interventional study of Eye Wash Solution Arm and Placebo Arm in Dry Eye, sponsored by Eye & ENT Hospital of Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Eye & ENT Hospital of Fudan University · Early Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.

Planned enrollment
67th of 83
30 · median 80
Started
2026
with 10 others
Phase 1
7 of 106
3 open now
Primary completion
2026-11
later than 18 of 29 live
Registered
106th of 106
by date
Lead sponsor
3 of 106
Eye & ENT Hospital of Fudan University

Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 67th largest by planned enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 18 of the 29 other live ones, and was the 106th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Dry Eye Syndromes with a site in China, or all of them as a file.
02

Study summary

A single-center, randomized, participant-masked, placebo-controlled, parallel-group clinical trial designed to evaluate the effectiveness and safety of a novel eye wash solution for the treatment of dry eye disease

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of at least 18 years at the time of signing the . Provision of written informed consent.
  • Tear film break-up time (TBUT) \< 10 seconds at both Visit 0 and Visit 1. Ocular Surface Disease Index (OSDI) score ≥ 13 at both Visit 0 and Visit 1. Meibomian gland dysfunction (MGD) score ≥ 3 at Visit 0 or Visit 1.
  • Presence of cloudy meibum; or 3 or 4 out of 5 meibomian glands expressible upon eyelid compression; or meibomian gland dropout count ≥ 5 at both Visit 0 and Visit 1.
  • Meibomian gland dysfunction scoring: MGD is scored based on the secretion of the central 5 meibomian glands of the lower eyelid. Each gland is scored from 0 to 3 (0 = normal; 1 = thick, yellow-white particles; 2 = paste-like secretion; 3 = no secretion or obstruction), with a total score of 0-15 [12].
  • Total corneal fluorescein staining score of 1 \< X \< 10 (sum of inferior, superior, central, nasal, and temporal regions) according to the National Eye Institute (NEI) grading system at both Visit 0 and Visit 1.
  • At both Visit 0 and Visit 1, at least one eye (the same eye) must meet all criteria of items 3, 4, 5, and 6 above.
  • Ability and willingness to follow instructions, including participation in all study assessments and visits.

Exclusion criteria

Exclusion Criteria:

  • Any abnormal findings on slit-lamp examination of the ocular surface at both Visit 0 and Visit 1, or any findings that, in the investigator's judgment, may affect study parameters, which may include ocular trauma, history of ocular trauma, or anterior membrane disease.
  • History of Stevens-Johnson syndrome; use of any oral medications known to cause dry eyes (e.g., antihistamines, antidepressants, etc.) within 1 month prior to Visit 0, or expected instability during the study period.
  • Active ocular infection; use of any topical antibiotics or topical within 14 days prior to the visit, or potential need for such treatment during the study. Any other eyelid margin treatments, such as meibomian gland expression, systemic antibiotics (e.g., tetracyclines), and oral supplements for eye diseases (e.g., lutein) must remain stable for 14 days prior to the visit and throughout the study period.
  • Receipt of LipiFlow, intense pulsed light (IPL), or any other procedures affecting the meibomian glands within 1 month prior to Visit 1.
  • Abnormal eyelid structure preventing complete eyelid closure, including entropion, ectropion, or floppy eyelid syndrome, which may cause partial conjunctival exposure or affect eyelid blinking function.
  • Placement or removal of a permanent punctal plug within 3 months prior to Visit 1 (or 6 months for dissolvable plugs); or expected placement or removal of a punctal plug at this visit, or expected dissolution of the punctal plug during the study.
  • Dry eye caused by scarring, radiation injury, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (commonly seen in vitamin A deficiency).
  • Ocular or periocular .
  • Corneal epithelial defect; significant confluent staining or filaments in any part of the cornea.
  • History of herpes keratitis.
  • Significant ocular allergy symptoms, or expected persistent allergic conditions during the study.
  • Diagnosis of active ocular or systemic infection (bacterial, viral, or fungal) accompanied by fever requiring antibiotic treatment.
  • Use of contact lenses within 14 days prior to Visit 0, or expected use of contact lenses during the study.
  • Any intraocular, corneal, or ocular laser surgery within the past 6 months, or any planned ocular and/or eyelid surgery during the study.
  • Employees of the clinical trial site directly involved in the management, administration, or support of this trial, or immediate family members of the same trial site.
  • Women who are pregnant, breastfeeding, or planning to become pregnant.
  • For women of , refusal to undergo urine pregnancy testing at Visit 0, Visit 1, Visit 2, and Visit 3 (or early termination visit) will be considered a refusal of testing. Non-childbearing potential is defined as permanently sterilized (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or (no menstruation for 12 consecutive months).
  • Women of childbearing potential not using effective . Acceptable contraceptive methods include: hormonal oral contraceptives, implantable contraceptive devices, injectable contraceptives, or transdermal contraceptives; mechanical spermicides combined with barrier devices such as a diaphragm or condom; intrauterine devices; or surgical sterilization of the partner. For women who are not sexually active, abstinence may be considered an effective contraceptive method; however, if the subject becomes sexually active during the trial, she must agree to use appropriate contraception as defined above for the remainder of the trial.
  • Presence of an uncontrolled systemic disease, in the investigator's judgment. Known allergic reaction to the drug or its components. Significant ocular or periocular rosacea that, in the investigator's judgment, interferes with the trial (e.g., clinically significant facial induration).
  • Pterygium in either eye.
  • Current participation in an investigational drug or device study, or use of an investigational drug or device within 60 days after Visit 1.
  • Non-use of any lipid-based artificial tears (e.g., perfluorohexyloctane ophthalmic solution, etc.), no application of warm compresses, and no use of any eye drops and/or "TrueTear™" device (intranasal tear neurostimulator) within 3 days prior to this visit.
  • Presence of systemic immune diseases, such as systemic lupuserythematosus, rheumatoid arthritis, ankylosing spondylitis, Sjögren's syndrome, etc.
  • Best-corrected visual acuity ≥ 4.3 in both eyes at Visit 0 and Visit 1 (5-point recording method on the international standard logarithmic visual acuity chart at 5 meters).
  • Any condition or circumstance (including language barriers) that, in the investigator's judgment, may place the subject at significant risk, may interfere with study results, or may significantly hinder the subject's participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Arm

    Drug: Placebo Arm

  • Experimental
    Eye Wash Solution Arm

    Drug: Eye Wash Solution Arm

Interventions

  • DrugEye Wash Solution Arm

    0.2% DHA eye wash solution, one drop per eye, 3 times daily (TID) for 28 days.

  • DrugPlacebo Arm

    Saline (NaCl 0.9 %), one drop per eye, 3 times daily (TID) for 28 days.

06

What researchers measure

Primary outcomes

  1. Change in Corneal Fluorescein Staining (CFS) Score

    Change from baseline in corneal fluorescein staining score (total score 0-15) in the study eye.

    Time frame: Baseline (Visit 1) to Day 28 (Visit 3)

  2. Change in Ocular Surface Disease Index (OSDI) Score

    Change from baseline in OSDI score (ranging from 0 to 100) to assess dry eye symptoms.

    Time frame: Baseline (Visit 1) to Day 28 (Visit 3)

07

Study locations

1 site
  • Fudan Eye, Ear, Nose and Throat Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2026, 0 months later.

Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940452
Responsible party
Jiaxu Hong (Department director, Eye & ENT Hospital of Fudan University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jiaxu Hong, Department chief
Contact
Jiaxu.hong@fdeent.org
021-64377134

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion